Your browser doesn't support javascript.
loading
Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Pediatric Patients.
Conover, Katie R; Absah, Imad; Ballal, Sonia; Brumbaugh, David; Cho, Stanley; Cardenas, Maria C; Knackstedt, Elizabeth Doby; Goyal, Alka; Jensen, M Kyle; Kaplan, Jess L; Kellermayer, Richard; Kociolek, Larry K; Michail, Sonia; Oliva-Hemker, Maria; Reed, Anna W; Weatherly, Madison; Kahn, Stacy A; Nicholson, Maribeth R.
Affiliation
  • Conover KR; From the Department of General Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
  • Absah I; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Mayo Clinic Children's Center, Rochester, MN.
  • Ballal S; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA.
  • Brumbaugh D; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital Colorado, Aurora, CO.
  • Cho S; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Texas Children's Hospital, Houston, TX.
  • Cardenas MC; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Mayo Clinic Children's Center, Rochester, MN.
  • Knackstedt ED; the Division of Pediatric Infectious Disease, University of Utah, Primary Children's Hospital, Salt Lake City, UT.
  • Goyal A; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children's Hospital, Palo Alto, CA.
  • Jensen MK; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Utah, Primary Children's Hospital, Salt Lake City, UT.
  • Kaplan JL; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Mass General Hospital for Children, Boston, MA.
  • Kellermayer R; the Division of Pediatric Infectious Disease, University of Utah, Primary Children's Hospital, Salt Lake City, UT.
  • Kociolek LK; the Division of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
  • Michail S; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital Los Angeles, Los Angeles, CA.
  • Oliva-Hemker M; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Johns Hopkins Children's Center, Baltimore, MD.
  • Reed AW; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Johns Hopkins Children's Center, Baltimore, MD.
  • Weatherly M; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA.
  • Kahn SA; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA.
  • Nicholson MR; the Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Monroe Carell Jr. Children's Hospital, Nashville, TN.
J Pediatr Gastroenterol Nutr ; 76(4): 440-446, 2023 04 01.
Article in En | MEDLINE | ID: mdl-36720105
ABSTRACT

OBJECTIVES:

We sought to evaluate the safety and effectiveness of fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (CDI) in pediatric immunocompromised (IC) patients.

METHODS:

This is a multicenter retrospective cohort study of pediatric participants who underwent FMT between March 2013 and April 2020 with 12-week follow-up. Pediatric patients were included if they met the definition of IC and were treated with FMT for an indication of recurrent CDI. We excluded patients over 18 years of age, those with incomplete records, insufficient follow-up, or not meeting study definition of IC. We also excluded those treated for Clostridioides difficile recurrence without meeting the study definition and those with inflammatory bowel disease without another immunocompromising condition.

RESULTS:

Of 59 pediatric patients identified at 9 centers, there were 42 who met inclusion and no exclusion criteria. Included patients had a median age of 6.7 years. Etiology of IC included solid organ transplantation (18, 43%), malignancy (12, 28%), primary immunodeficiency (10, 24%), or other chronic conditions (2, 5%). Success rate was 79% after first FMT and 86% after 1 or more FMT. There were no statistically significant differences in patient characteristics or procedural components when patients with a failed FMT were compared to those with a successful FMT. There were 15 total serious adverse events (SAEs) in 13 out of 42 (31%) patients that occurred during the follow-up period; 4 (9.5%) of which were likely treatment-related. There were no deaths or infections with multidrug resistant organisms during follow-up and all patients with a SAE fully recovered.

CONCLUSIONS:

The success rate of FMT for recurrent CDI in this pediatric IC cohort is high and mirrors data for IC adults and immunocompetent children. FMT-related SAEs do occur (9.5%) and highlight the need for careful consideration of risk and benefit.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clostridioides difficile / Clostridium Infections Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Humans Language: En Journal: J Pediatr Gastroenterol Nutr Year: 2023 Document type: Article Affiliation country: Tunisia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clostridioides difficile / Clostridium Infections Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Humans Language: En Journal: J Pediatr Gastroenterol Nutr Year: 2023 Document type: Article Affiliation country: Tunisia